Valbiotis Expands Its Reach in Asia

On May 11, 2026, Valbiotis announced a strategic milestone with the establishment of a subsidiary in Singapore through its Chinese joint venture, Hangzhou Valbiotis Life Health Technology. This move marks a key step towards expanding Valbiotis' presence in Asia, targeting markets like Singapore, Vietnam, Indonesia, and Japan. The initiative supports Valbiotis' ambition to become a leader in preventing cardiometabolic imbalances using natural, clinically tested solutions.

The expansion plan involves leveraging both e-commerce and traditional distribution networks, with product launches contingent on local regulatory approvals. Additionally, Valbiotis plans to commence commercial operations in China in late 2026, utilizing partner cross-border e-commerce platforms to penetrate the Chinese market.

Valbiotis' joint venture in Asia, in which it holds a 49% stake, seeks to offer products tailored specifically for the Asian consumer base. This strategic move promises to enhance Valbiotis' footprint in the region, tapping into significant market potential.